Skip Navigation



Cardiovascular Research Advance Access [Accepted Manuscript] published online on March 22, 2009

Cardiovascular Research, doi:10.1093/cvr/cvp097
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
83/2/388    most recent
cvp097v2
cvp097v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Chappell, D.
Right arrow Articles by Becker, B. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chappell, D.
Right arrow Articles by Becker, B. F.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.

Antithrombin reduces shedding of the endothelial glycocalyx following ischemia/reperfusion

Daniel Chappell1,3, Matthias Jacob1,3, Klaus Hofmann-Kiefer1, Markus Rehm1, Ulrich Welsch2, Peter Conzen1 and Bernhard F. Becker3

1 Clinic of Anesthesiology, Ludwig-Maximilians-University Munich
2 Institute of Anatomy, Ludwig-Maximilians-University Munich
3 Walter-Brendel-Centre of Experimental Medicine, Ludwig-Maximilians-University Munich

Corresponding author: Dr. Daniel Chappell, Clinic of Anesthesiology, Ludwig-Maximilians-University Munich, Nussbaumstrasse 20, 80336 Munich, Germany, Tel.: +49-89-2180-75382, Fax: +49-89-5160-4446, E-mail: daniel.chappell{at}med.uni-muenchen.de

Aims: Antithrombin is an important inhibitor of the coagulation system, additionally exerting specific anti-inflammatory effects on endothelial cells. Healthy vascular endothelium is coated by the endothelial glycocalyx, diminution of which increases capillary permeability, e.g., after ischemia. Antithrombin is known to infiltrate the glycocalyx, binding to glycosaminoglycans, and to preserve the glycocalyx after application tumor necrosis factor-{alpha}. We investigated the influence of antithrombin on glycocalyx subjected to ischemia/reperfusion.

Methods: Isolated guinea pig hearts were perfused with Krebs-Henseleit buffer (KHB). Antithrombin was applied to achieve physiological levels (1 U/ml) before inducing 20 min of ischemia (37°C). Hearts were reperfused for 20 min at constant flow (baseline perfusion pressure 70cmH2O) with KHB or KHB plus 2 g% hydroxyethylstarch (130kD). Coronary net fluid filtration was assessed directly by measuring transudate formation on the epicardial surface. Postischemic coronary release of syndecan-1 and heparan sulfate was quantified by ELISA. Hearts were perfusion-fixed to visualize the glycocalyx by electron microscopy.

Results: Ischemia/reperfusion caused degradation of the glycocalyx, enhanced coronary perfusion pressure and increased vascular permeability. Antithrombin significantly reduced postischemic glycocalyx shedding, coronary perfusion pressure, coronary leak and tissue edema formation compared to untreated hearts. Additional application of colloid augmented these actions of antithrombin. Electron microscopy revealed a mostly intact glycocalyx after antithrombin treatment.

Conclusions: Antithrombin preserves the endothelial glycocalyx, sustaining the vascular barrier function and reducing interstitial edema. The potentiated effect of colloid in these hearts suggests that the prevention of shedding should be of functional benefit also in vivo.

KEYWORDS Endothelial function; Ischemia; Antithrombin; Glycocalyx; Vascular leak


Time for primary review: 40 Days

The work was performed at: Clinic of Anesthesiology and Walter-Brendel-Centre of Experimental Medicine, Ludwig-Maximilians-University, Munich, Germany.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.